Seeking Alpha
20 Nov 2026, 01:24 UTC · 1h ago
IHE: 21% Next-Year EPS Growth Supports More Upside For U.S. Pharmaceuticals
Impact · against what's priced in
The article provides a bullish outlook based on aggregate ETF growth estimates, but offers no new company-specific catalysts. For the underlying holdings, the generic sector growth mentioned is already largely captured in their current valuations.
- JNJ+0.00
Already priced in
- The price assumes
raised 2026 revenue guidance of $100.3–$101.3 billion
General pharmaceutical sector growth of 21% confirms the operational trajectory and guidance the price has already absorbed for Johnson & Johnson.





